Commonly Reported Mosquito-Borne Viruses in the United States: A Primer for Pharmacists

Abstract

Mosquito-borne diseases are a public health concern. Pharmacists are often a patient’s first stop for health information and may be asked questions regarding transmission, symptoms, and treatment of mosquito borne viruses (MBVs). The objective of this paper is to review transmission, geographic location, symptoms, diagnosis and treatment of MBVs. We discuss the following viruses with cases in the US in recent years: Dengue, West Nile, Chikungunya, LaCrosse Encephalitis, Eastern Equine Encephalitis Virus, and Zika. Prevention, including vaccines, and the impact of climate change are also discussed.

Keywords

mosquito virus dengue west nile chikungunya lacrosse encephalitis eastern equine encephalitis virus zika

Get full access to this article

View all access options for this article.

References

Norman

. Americans rate healthcare providers high on honesty, ethics. https://news.gallup.com/poll/200057/americans-rate-healthcare-providers-high-honesty-ethids.aspx. Published December 19, 2016. Accessed February 10, 2022.

Tsuyuki

Beahm

Okada

Al Hamarneh

. Pharmacists as accessible primary health care providers: Review of the evidence. Can Pharm J. 2018;151(1):4. doi:10.1177/1715163517745517.

Patwardhan

Duncan

Murphy

Pegus

. The value of pharmacists in health care. Popul Health Manag. 2012;15(3):157-2. doi:10.1089/pop.2011.0030.

Dengue in the US states and territories | dengue | CDC. https://www.cdc.gov/dengue/areaswithrisk/in-the-us.html. Published October 7, 2020. Accessed February 10, 2022.

Final annual maps and data | West Nile virus | CDC. https://www.cdc.gov/westnile/statsmaps/finalmapsdata/index.html. Published December 17, 2021. Accessed February 10, 2022.

Chikungunya in the US | Chikungunya virus | CDC. https://www.cdc.gov/chikungunya/geo/chikungunya-in-the-us.html. Published February 23, 2022. Accessed December 7, 2022.

Statistics and maps | La Crosse encephalitis | CDC. https://www.cdc.gov/lac/statistics/index.html. Published January 7, 2022. Accessed February 10, 2022.

Statistics and maps | Eastern equine encephalitis | CDC. https://www.cdc.gov/easternequineencephalitis/statistics-maps/index.html. Published December 16, 2021. Accessed February 10, 2022.

CDC . Reporting and surveillance - Zika virus. Centers for disease control and prevention. http://www.cdc.gov/zika/reporting/index.html. Published January 12, 2017. Accessed February 10, 2022.

10.

CDC

About

Dengue| CDc. centers for disease control and prevention. https://www.cdc.gov/dengue/about/index.html. Published September 23, 2021. Accessed February 10, 2022.

11.

Guzman

Kouri

. Dengue and dengue hemorrhagic fever in the Americas: Lessons and challenges. J Clin Virol. 2003;27(1):1. doi:10.1016/S1386-6532(03)00010-6.

12.

Prevention | dengue | CDC. https://www.cdc.gov/dengue/prevention/index.html. Published September 30, 2021. Accessed February 10, 2022.

13.

Statistics and maps | dengue | CDC. https://www.cdc.gov/dengue/statistics-maps/index.html. Published February 2, 2022. Accessed February 10, 2022.

14.

Garmendia

Van Kruiningen

French

. The West Nile virus: its recent emergence in North America. Microb Infect. 2001;3(3):223-9. doi:10.1016/S1286-4579(01)01374-0.

15.

David

Abraham

. Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen. Inf Disp. 2016;48(8):571-6. doi:10.3109/23744235.2016.1164890.

16.

Areas at risk for Chikungunya | Chikungunya virus | CDC. https://www.cdc.gov/chikungunya/geo/index.html. Published March 4, 2022. Accessed August 11, 2022.

17.

Clinical evaluation and disease | Chikungunya virus | CDC. https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html. Published February 2, 2022. Accessed February 10, 2022.

18.

Transmission | La Crosse encephalitis | CDC. https://www.cdc.gov/lac/transmission/index.html. Published January 7, 2022. Accessed February 10, 2022.

19.

Transmission | Eastern equine encephalitis | CDC. https://www.cdc.gov/easternequineencephalitis/transmission/index.html. Published September 7, 2021. Accessed February 10, 2022.

20.

What we know about Zika. CDC. https://www.cdc.gov/zika/about/index.html. Published November 5, 2014. Accessed February 10, 2022.

21.

Flaviviridae | viral hemorrhagic fevers (VHFs) | CDC. https://www.cdc.gov/vhf/virus-families/flaviviridae.html. Published March 23, 2022. Accessed December 13, 2022.

22.

Guzman

Kouri

. Dengue diagnosis, advances and challenges. Int J Infect Dis. 2004;8(2):69. doi:10.1016/j.ijid.2003.03.003.

23.

Clinical evaluation and disease | West Nile virus | CDC. https://www.cdc.gov/westnile/healthcareproviders/healthCareProviders-ClinLabEval.html. Published July 7, 2021. Accessed February 11, 2022.

24.

Powers

Logue

. Changing patterns of Chikungunya virus: Re-emergence of a zoonotic arbovirus. J Gen Virol. 2007;88(9):2363-77. doi:10.1099/vir.0.82858-0.

25.

Symptoms, diagnosis, and treatment | Chikungunya virus | CDC. https://www.cdc.gov/chikungunya/symptoms/index.html. Published January 13, 2022. Accessed February 11, 2022.

26.

Virus | La Crosse encephalitis | CDC. https://www.cdc.gov/lac/virus/index.html. Published January 7, 2022. Accessed February 11, 2022.

27.

Symptoms, diagnosis, and treatment | La Crosse encephalitis | CDC. https://www.cdc.gov/lac/symptoms/index.html. Published January 7, 2022. Accessed February 11, 2022.

28.

Virus | eastern equine encephalitis | CDC. https://www.cdc.gov/easternequineencephalitis/virus/index.html. Published August 26, 2021. Accessed February 15, 2022.

29.

Symptoms, diagnosis, and treatment | eastern equine encephalitis | CDC. https://www.cdc.gov/easternequineencephalitis/symptoms-diagnosis-treatment/index.html. Published September 7, 2021. Accessed February 15, 2022.

30.

Krow-Lucal

Biggerstaff

Staples

. Estimated incubation period for zika virus disease. Emerg Infect Dis. 2017;23(5):841-5. doi:10.3201/eid2305.161715.

31.

CDC . Dengue transmission | CDC. Centers for disease control and prevention. https://www.cdc.gov/dengue/transmission/index.html. Published September 26, 2019. Accessed February 10, 2022.

32.

Wikramaratna

Simmons

Gupta

Recker

. The effects of tertiary and quaternary infections on the epidemiology of dengue. PLoS One. 2010;5(8):e12347. doi:10.1371/journal.pone.0012347.

33.

Goncalvez

Engle

St Claire

Purcell

Lai

. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007;104(22):9422-27. doi:10.1073/pnas.0703498104.

34.

Sierra

Pérez

Alvarez

, et al. Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus. Am J Trop Med Hyg. 2012;87(3):538-7. doi:10.4269/ajtmh.2012.11-0531.

35.

Cummings

DAT

Schwartz

Billings

Shaw

Burke

. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci U S A. 2005;102(42):15259-64. doi:10.1073/pnas.0507320102.

36.

Dengue during pregnancy | dengue | CDC. https://www.cdc.gov/dengue/transmission/pregnancy.html. Published November 14, 2019. Accessed February 10, 2022.

37.

Paixão

Teixeira

Costa

MCN

Rodrigues

. Dengue during pregnancy and adverse fetal outcomes: A systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):857-5. doi:10.1016/S1473-3099(16)00088-8.

38.

Areas with risk of dengue | dengue | CDC. https://www.cdc.gov/dengue/areaswithrisk/index.html. Published November 5, 2021. Accessed February 11, 2022.

39.

Testing guidance | dengue | CDC. https://www.cdc.gov/dengue/healthcare-providers/testing/testing-guidance.html. Published January 24, 2020. Accessed February 11, 2022.

40.

Diagnosis | dengue | CDC. https://www.cdc.gov/dengue/healthcare-providers/diagnosis.html. Published August 21, 2019. Accessed February 11, 2022.

41.

Dengue

CDC

. Symptoms and treatment| CDC. centers for disease control and prevention. https://www.cdc.gov/dengue/symptoms/index.html. Published September 20, 2021. Accessed February 11, 2022.

42.

Guzman

Gubler

Izquierdo

Martinez

Halstead

. Dengue infection. Nat Rev Dis Prim. 2016;2(1):16055. doi:10.1038/nrdp.2016.55.

43.

Horstick

Martinez

Guzman

Martin

JLS

Ranzinger

. WHO dengue case classification 2009 and its usefulness in practice: An expert consensus in the Americas. Pathog Glob Health. 2015;109(1):19-5. doi:10.1179/2047773215Y.0000000003.

44.

Clinical presentation | dengue | CDC. https://www.cdc.gov/dengue/healthcare-providers/clinical-presentation.html. Published September 13, 2021. Accessed August 11, 2022.

45.

Oishi

Saito

Mapua

Natividad

. Dengue illness: Clinical features and pathogenesis. J Infect Chemother. 2007;13(3):125-3. doi:10.1007/s10156-007-0516-9.

46.

Chuansumrit

Chaiyaratana

. Hemostatic derangement in dengue hemorrhagic fever. Thromb Res. 2014;133(1):10-6. doi:10.1016/j.thromres.2013.09.028.

47.

Kaur

. Transfusion support in patients with dengue fever. Int J Appl Basic Med Res. 2014;4(3):8-2. doi:10.4103/2229-516X.140708.

48.

Tian

Zhou

Takagi

Kameoka

Kawashita

. Dengue virus and its inhibitors: A brief review. Chem Pharm Bull. 2018;66(3):191-6. doi:10.1248/cpb.c17-00794.

49.

Deen

von Seidlein

. Paracetamol for dengue fever: No benefit and potential harm? Lancet Global Health. 2019;7(5):e552-3. doi:10.1016/S2214-109X(19)30157-3.

50.

Vasikasin

Rojdumrongrattana

Chuerboonchai

, et al. Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled trial. Lancet Global Health. 2019;7(5):e664. doi:10.1016/S2214-109X(19)30032-4.

51.

Wandt

Frank

Ehninger

, et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91(10):3601-6.

52.

Lye

Lee

Sun

Leo

. Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin Infect Dis. 2009;48(9):1262-5. doi:10.1086/597773.

53.

Lum

LCS

Abdel-Latif

MEA

Goh

AYT

Chan

PWK

Lam

. Preventive transfusion in dengue shock syndrome–is it necessary? J Pediatr. 2003;143(5):682-4. doi:10.1067/S0022-3476(03)00503-1.

54.

Symptoms, diagnosis, and treatment | West Nile virus | CDC. https://www.cdc.gov/westnile/symptoms/index.html. Published July 22, 2021. Accessed February 11, 2022.

55.

McJunkin

Khan

Tsai

. California–La Crosse encephalitis. Infect Dis Clin. 1998;12(1):83-3. doi:10.1016/S0891-5520(05)70410-4.

56.

Sokol

Kleiman

Garg

. LaCrosse viral encephalitis mimics herpes simplex viral encephalitis. Pediatr Neurol. 2001;25(5):413-5. doi:10.1016/S0887-8994(01)00337-X.

57.

Wurtz

Paleologos

. La Crosse encephalitis presenting like herpes simplex encephalitis in an immunocompromised adult. Clin Infect Dis. 2000;31(4):1113-4. doi:10.1086/321804.

58.

Zika Virus. CDC. https://www.cdc.gov/zika/hc-providers/preparing-for-zika/clinicalevaluationdisease.html. Published November 5, 2014. Accessed February 15, 2022.

59.

Commissioner O of the. First FDA-approved vaccine for the prevention of dengue disease in endemic regions. FDA. https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-dengue-disease-endemic-regions. Published May 1, 2019. Accessed February 11, 2022.

60.

Bernard

Kramer

. West nile virus activity in the United States, 2001. Viral Immunol. 2001;14(4):319-8. doi:10.1089/08828240152716574.

61.

Transmission | West Nile virus | CDC. https://www.cdc.gov/westnile/transmission/index.html. Published July 22, 2021. Accessed February 11, 2022.

62.

West Nile virus and dead birds | West Nile virus | CDC. https://www.cdc.gov/westnile/dead-birds/index.html. Published July 22, 2021. Accessed February 11, 2022.

63.

Mother to baby during pregnancy, delivery, or breast feeding | West Nile virus | CDC. https://www.cdc.gov/westnile/transmission/pregnancy.html. Published July 7, 2021. Accessed February 11, 2022.

64.

West Nile virus | West Nile virus | CDC. https://www.cdc.gov/westnile/index.html. Published June 2, 2022. Accessed February 11, 2022.

65.

Diagnostic testing | West Nile virus | CDC. https://www.cdc.gov/westnile/healthcareproviders/healthCareProviders-Diagnostic.html. Published July 7, 2021. Accessed February 11, 2022.

66.

Petersen

Jamieson

Powers

Honein

. Zika virus. In: Baden

, ed. N Engl J Med. 2016;374(16):1552-3. doi:10.1056/NEJMra1602113.

67.

Treatment and Prevention . | West nile virus | CDC. https://www.cdc.gov/westnile/healthcareproviders/healthCareProviders-TreatmentPrevention.html. Published November 10, 2021. Accessed February 11, 2022.

68.

Diamond

. Progress on the development of therapeutics against west nile virus. Antivir Res. 2009;83(3):214-7. doi:10.1016/j.antiviral.2009.05.006.

69.

Beasley

DWC

. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy. 2011;3(2):269-5. doi:10.2217/imt.10.93.

70.

Staples

Breiman

Powers

. Chikungunya fever: An epidemiological review of a re-emerging infectious disease. Clin Infect Dis. 2009;49(6):942-8. doi:10.1086/605496.

71.

Thiberville

Moyen

Dupuis-Maguiraga

, et al. Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy. Antivir Res. 2013;99(3):345. doi:10.1016/j.antiviral.2013.06.009.

72.

Weaver

Osorio

Livengood

Chen

Stinchcomb

. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012;11(9):1087-1. doi:10.1586/erv.12.84.

73.

Queyriaux

Simon

Grandadam

Michel

Tolou

Boutin

. Clinical burden of chikungunya virus infection. Lancet Infect Dis. 2008;8(1):2. doi:10.1016/S1473-3099(07)70294-3.

74.

Diagnostic testing | Chikungunya virus | CDC. https://www.cdc.gov/chikungunya/hc/diagnostic.html. Published January 13, 2022. Accessed February 11, 2022.

75.

Rust

Thompson

Matthews

Beaty

Chun

RWM

. Topical review: La Crosse and other forms of California encephalitis. J Child Neurol. 1999;14(1):1. doi:10.1177/088307389901400101.

76.

Teleron

ALA

Rose

Williams

Kemper

McJunkin

. La crosse encephalitis: An adult case series. Am J Med. 2016;129(8):881-4. doi:10.1016/j.amjmed.2016.03.021.

77.

McJunkin

de los Reyes

Irazuzta

, et al. La Crosse encephalitis in children. N Engl J Med. 2001;344(11):801-7. doi:10.1056/NEJM200103153441103.

78.

Balkhy

Schreiber

. Severe La Crosse encephalitis with significant neurologic sequelae. Pediatr Infect Dis J. 2000;19(1):77. doi:10.1097/00006454-200001000-00016.

79.

Zika virus transmission. CDC. https://www.cdc.gov/zika/prevention/transmission-methods.html. Published November 5, 2014. Accessed December 14, 2022.

80.

Vouga

Musso

Goorhuis

Freedman

Baud

. Updated Zika virus recommendations are needed. Lancet. 2018;392(10150):818-9. doi:10.1016/S0140-6736(18)31827-0.

81.

Zika Virus. CDC. https://www.cdc.gov/zika/hc-providers/clinical-guidance/sexualtransmission.html. Published November 5, 2014. Accessed February 15, 2022.

82.

CDC. Data and statistics on zika and pregnancy | CDC. Centers for disease control and prevention. https://www.cdc.gov/pregnancy/zika/data/index.html. Published March 17, 2022. Accessed August 11, 2022.

83.

CDC . Caring for pregnant women | zika and pregnancy | CDC. Centers for disease control and prevention. https://www.cdc.gov/pregnancy/zika/testing-follow-up/pregnant-woman.html. Published March 25, 2021. Accessed February 15, 2022.

84.

Paz-Bailey

Rosenberg

Doyle

, et al. Persistence of Zika virus in body fluids — final report. N Engl J Med. 2018;379(13):1234-3. doi:10.1056/NEJMoa1613108.

85.

Zika

CDC

. Infants and children | zika and pregnancy | CDC. Centers for disease control and prevention. https://www.cdc.gov/pregnancy/zika/testing-follow-up/zika-in-infants-children.html. Published March 31, 2022. Accessed in February 15, 2022.

86.

Moore

Scott

Rodriguez

, et al. An online survey of personal mosquito-repellent strategies. PeerJ. 2018;6:e5151. doi:10.7717/peerj.5151.

87.

Fradin

Day

. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med. 2002;347(1):13-8. doi:10.1056/NEJMoa011699.

88.

US EPA O . Using insect repellents safely and effectively. https://www.epa.gov/insect-repellents/using-insect-repellents-safely-and-effectively. Published July 15, 2013. Accessed March 25, 2022.

89.

US EPA O . Regulation of skin-applied repellents. https://www.epa.gov/insect-repellents/regulation-skin-applied-repellents. Published July 15, 2013. Accessed March 25, 2022.

90.

US EPA O . DEET. https://www.epa.gov/insect-repellents/deet. Published July 15, 2013. Accessed March 25, 2022.

91.

US EPA O . Find the repellent that is right for you. https://www.epa.gov/insect-repellents/find-repellent-right-you. Published August 20, 2013. Accessed March 25, 2022.

92.

Prevent mosquito bites | mosquitoes | CDC. https://www.cdc.gov/mosquitoes/mosquito-bites/prevent-mosquito-bites.html. Published July 12, 2022. Accessed February 15, 2022.

93.

CDC . How to use permethrin | CDC. Centers for disease control and prevention. https://www.cdc.gov/mosquitoes/mosquito-bites/how-to-use-permethrin.html. Published March 18, 2020. Accessed March 25, 2022.

94.

Deng

Yang

Wei

Chen

Wang

Peng

. A review on dengue vaccine development. Vaccines. 2020;8(1):63. doi:10.3390/vaccines8010063.

95.

Aggarwal

Garg

. Newer vaccines against mosquito-borne diseases. Indian J Pediatr. 2018;85(2):117-3. doi:10.1007/s12098-017-2383-4.

96.

Silva

Santos

Martins

. Dengue and Zika viruses: epidemiological history, potential therapies, and promising vaccines. Trav Med Infect Dis. 2020;5(4):150. doi:10.3390/tropicalmed5040150.

97.

Ulbert

. West Nile virus vaccines – current situation and future directions. Hum Vaccines Immunother. 2019;15(10):2337-2. doi:10.1080/21645515.2019.1621149.

98.

Kaiser

Barrett

ADT

. Twenty years of progress toward west nile virus vaccine development. Viruses. 2019;11(9):3. doi:10.3390/v11090823.

99.

Pierson

Cardile

Okwesili

, et al. Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine. Vaccine. 2021;39(20):2780-90. doi:10.1016/j.vaccine.2021.03.030.

100.

Chen

Coates

Plummer

, et al. Effect of a Chikungunya virus–like particle vaccine on safety and tolerability outcomes: A randomized clinical trial. JAMA. 2020;323(14):1369-7. doi:10.1001/jama.2020.2477.

101.

Bennett

Gresko

Nelson

Murphy

Whitehead

. A recombinant chimeric La Crosse virus expressing the surface glycoproteins of jamestown canyon virus is immunogenic and protective against challenge with either parental virus in mice or Monkeys. J Virol. 2012;86(1):420-6. doi:10.1128/JVI.02327-10.

102.

Mordecai

Caldwell

Grossman

, et al. Thermal biology of mosquito-borne disease. Ecol Lett. 2019;22(10):1690-8. doi:10.1111/ele.13335.

103.

Reinhold

Lazzari

Lahondère

. Effects of the environmental temperature on aedes aegypti and aedes albopictus mosquitoes: A review. Insects. 2018;9(4):158. doi:10.3390/insects9040158.

104.

Becker

. Influence of climate change on mosquito development and mosquito-borne diseases in Europe. Parasitol Res. 2008;103(S1):19-8. doi:10.1007/s00436-008-1210-2.

105.

Patz

Graczyk

Geller

Vittor

. Effects of environmental change on emerging parasitic diseases. Int J Parasitol. 2000;30(12-13):1395-5. doi:10.1016/S0020-7519(00)00141-7.

106.

Reiter

. Climate change and mosquito-borne disease. Environ Health Perspect. 2001;109(suppl 1):141-1. doi:10.1289/ehp.01109s1141.

107.

Robert

Stewart-Ibarra

Estallo

. Climate change and viral emergence: Evidence from aedes-borne arboviruses. Curr Opin Virol. 2020;40:41-7. doi:10.1016/j.coviro.2020.05.001.

108.

Colón-González

Sewe

Tompkins

, et al. Projecting the risk of mosquito-borne diseases in a warmer and more populated world: a multi-model, multi-scenario intercomparison modelling study. Lancet Planet Health. 2021;5(7):e404-4. doi:10.1016/S2542-5196(21)00132-7.

109.

Lowe

Gasparrini

Van Meerbeeck

, et al. Nonlinear and delayed impacts of climate on dengue risk in Barbados: A modelling study. In: Thomson

, ed. PLoS Med 2018;15(7):e1002613. doi:10.1371/journal.pmed.1002613.

110.

Paull

Horton

Ashfaq

, et al. Drought and immunity determine the intensity of West Nile virus epidemics and climate change impacts. Proc Biol Sci. 2017;284(1848):20162078. doi:10.1098/rspb.2016.2078.

111.

Hamer

Walker

Brawn

, et al. Rapid amplification of West Nile virus: The role of hatch-year birds. Vector Borne Zoonotic Dis. 2008;8(1):57-7. doi:10.1089/vbz.2007.0123.

112.

Gervasi

Burkett-Cadena

Burgan

, et al. Host stress hormones alter vector feeding preferences, success, and productivity. Proc Biol Sci. 2016;283(1836):20161278. doi:10.1098/rspb.2016.1278.